The great debate: Stopping immunomodulators and biologics in Crohn's disease patients in remission

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 6, 2013, Pages 501-503

  Hashash, Jana G ^a   Regueiro, Miguel D ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

anti TNF therapy; immunomodulator therapy; Predictors of relapse

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CROHN DISEASE; DISEASE EXACERBATION; EDITORIAL; HUMAN; MONOTHERAPY; RECURRENT DISEASE; RELAPSE; REMISSION; SMOKING;

BIOLOGICAL PRODUCTS; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887839310     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.814933     Document Type: Editorial

References (6)

1. Camus M, Seksik P, Bourrier A et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin. Gastroenterol. Hepatol. 11(4), 389-394 (2013).
2. Louis E, Mary JY, Vernier-Massouille G et al.; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63-70.e5; quiz e31 (2012).
3. Molnár T, Lakatos PL, Farkas K et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment. Pharmacol. Ther. 37(2), 225-233 (2013).
4. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am. J. Gastroenterol. 105(5), 1142-1149 (2010).
5. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134(7), 1861-1868 (2008). (Pubitemid 351790744)
6. Waugh AW, Garg S, Matic K et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32(9), 1129-1134 (2010).